Decipher® delivers unique, personalized and actionable results to inform treatment decisions after biopsy and surgery1, 2, 3
- Decipher analyzes the expression of 22 biomarkers across the genome to generate a robust genomic risk score
Decipher Biopsy reports a score to predict the likelihood of metastasis, high-grade disease and prostate cancer specific death for men diagnosed with localized disease.
Easy to interpret
Decipher Biopsy is based on patients’ personal tumor-based genomics, to help determine who:
- May be suitable candidates for active surveillance
- May be treated with local therapy alone
- May benefit from intensification of multi-modal therapy
|Decipher Classification||Patient Management Recommendations|
|Genomic Low Risk||Favorable prognosis – may be suitable candidate for active surveillance and may have excellent outcomes when treated with local therapy alone|
|Genomic High Risk||Unfavorable prognosis – may not be suitable candidate for active surveillance and may benefit from intensification with multi-modal therapy|
Click here to download the Decipher Biopsy Sample Test report
Decipher Post-Op reports a score to predict the likelihood of metastasis and prostate cancer specific death for men after prostatectomy surgery.
Easy to interpret
Patients are identified as High, Average or Low risk based on their predicted probability of developing metastasis and prostate cancer specific death.
|Decipher Classification||Treatment recommended post-surgery||Treatment recommended post-surgery after PSA rise or biochemical recurrence (BCR)|
|Genomic Low Risk||Observation with PSA monitoring until detectable PSA rise, if any/ever
||Radiation alone is sufficient. Concurrent hormone therapy may be avoided.|
|Genomic High Risk||80% reduction in metastasis risk in Decipher high-risk patients who receive adjuvant or early radiation||Radiation alone is insufficient. Intensification of treatment may be needed.|
Decipher tells you something new for 80% of patients tested
In clinical studies, Decipher reclassified 80% of clinically high-risk patients after surgery to lower (60%) or higher (20%) risk categories.
Summary of key data for Decipher
Click here to download the Decipher Post-op Sample Test report